Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: A randomised, double-blind, placebo-controlled trial

The Lancet Respiratory Medicine

Volumn 2, Issue 1, 2014, Pages 63-72

  Watz, Henrik ^a   Barnacle, Helen ^b   Hartley, Benjamin F ^b   Chan, Robert ^b  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOSMAPIMOD; PLACEBO; 6-(5-((CYCLOPROPYLAMINO)CARBONYL)-3-FLUORO-2-METHYLPHENYL)-N-(2,2-DIMETHYLPRPYL)-3-PYRIDINECARBOXAMIDE; CYCLOPROPANE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; WALKING; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

ACUTE DISEASE; ADULT; AGED; CYCLOPROPANES; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDINES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84891373802     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70200-5     Document Type: Article

References (48)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
2. Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMJW Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22.
3. Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11:63.
4. Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008, 177:743-751.
5. Garcia-Aymerich J, Serra I, Gomez FP, et al. Physical activity and clinical and functional status in COPD. Chest 2009, 136:62-70.
6. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009, 136:1039-1046.
7. Engström G, Segelstorm N, Ekberg-Aronsson M, Nilsson PM, Lindgärde F, Löfdahl C-G Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax 2009, 64:211-215.
8. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7:e37483.
9. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072.
10. Decramer M, Janssens W Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013, 1:73-83.
11. Mercer BA, D'Armiento JM Emerging role of MAP kinase pathways as therapeutic targets in COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:137-150.
12. Elkhawad M, Rudd JHF, Sarov-Blat L, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging 2012, 5:911-922.
13. Martin ED, De Nicola GF, Marber MS New therapeutic targets in cardiology p38 alpha mitogen-activated protein kinase for ischemic heart disease. Circulation 2012, 126:357-368.
14. Marber MS, Rose B, Wang Y The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011, 51:485-490.
15. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31:62-69.
16. Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J 2013, 42:28-41.
17. Lemire BB, Debigaré R, Dubé A, Thériault M-E, CÔté CH, Maltais F MAPK signaling in the quadriceps of patients with chronic obstructive pulmonary disease. J Appl Physiol 2012, 113:159-166.
18. Armstrong J, Harbron C, Lea S, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011, 338:732-740.
19. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 2010, 50:94-100.
20. Chung KF p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011, 139:1470-1479.
21. Singh D p38 inhibition in COPD; cautious optimism. Thorax 2013, 68:705-706.
22. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012, 52:416-424.
23. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.
24. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012, 106:522-530.
25. Watz H, Waschki B, Meyer T, Magnussen H Physical activity in patients with COPD. Eur Respir J 2009, 33:262-272.
26. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
27. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
28. Meguro M, Barley EA, Spencer S, Jones PW Development and validation of an improved, COPD specific version of the St. George Respiratory Questionnaire. Chest 2007, 132:456-463.
29. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648-654.
30. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010, 91:221-225.
31. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011, 37:784-790. National Emphysema Treatment Trial (NETT) Research Group.
32. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease. Minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013, 187:382-386.
33. Hernandes NA, Wouters EFM, Meijere K, Annegarne J, Pitta F, Spruit MA Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J 2011, 38:261-267.
34. O'Donnell DE, Bredenbröker D, Brose M, Webb KA Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J 2012, 39:1104-1112.
35. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012, 67:701-708.
36. Calverley PMA, Albert P, Walker PP Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med 2013, 1:564-573.
37. MacNee W, Allan RJ, Jones L, De Salvo MC, Tan LF Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2012, 68:738-745.
38. Barnes PJ, Celli BR Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
39. Bourdin A, Burgel P-R, Chanez P, Garcia G, Perez T, Roche N Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. Eur Respir Rev 2009, 18:198-212.
40. Casaburi R, Celli B, Crapo J, et al. The COPD Biomarker Qualification Consortium (CBQC). COPD 2013, 10:367-377.
41. Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008, 26:97-102.
42. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlosser NJ, Wouters EF Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357.
43. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2012, 68:670-676.
44. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
45. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010, 53:2345-2353.
46. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013, 1:210-223.
47. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694. M2-124 and M2-125 study groups.
48. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.